1. A1.38 Mesenchymal stem cells induce non-classical IL-10-producing regulatory TH17 cells in arthritis: role of gilz. (31st January 2014) Authors: Luz-Crawford, P; Tejedor, G; Bonnefont, A L; Morand, E; Beaulieu, E; Jorgensen, C; Noël, D; Djouad, F Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 1(2014) Page Start: A16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A8.11 gilz-dependent activin a production by MSC inhibits TH17 differentiation. (31st January 2014) Authors: Luz-Crawford, P; Tejedor, G; Ipseiz, N; Pène, J; Morand, E; Beaulieu, E; Jorgensen, C; Noël, D; Djouad, F Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 1(2014) Page Start: A80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. (December 2019) Authors: Kandane-Rathnayake, R; Kent, J R; Louthrenoo, W; Luo, S -F; Wu, Y -JJ; Lateef, A; Golder, V; Sockalingam, S; Navarra, S a; Zamora, L; Hamijoyo, L; Katsumata, Y; Harigai, M; Chan, M; O'Neill, S; Goldblatt, F; Lau, C S; Hoi, A; Nikpour, M; Morand, E Journal: Lupus Issue: Volume 28:Number 14(2019) Page Start: 1669 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0001 The lupus low disease activity state (LLDAS) definition discriminates responders in a systemic lupus erythematosus (SLE) trial: post-hoc analysis of the phase iib muse trial of anifrolumab. (15th June 2017) Authors: Morand, E; Berglind, A; Sheytanova, T; Tummala, R; Illei, G Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. (27th September 2022) Authors: Van Vollenhoven, R; Pike, M; Merrill, JT; Morand, E; Werth, VP; Hobar, C; Delev, N; Shah, V; Sharkey, B; Wegman, T; Catlett, I; Banerjee, S; Singhal, S Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S7A:5 Sri response, attainment of low disease activity and safety in patients with systemic lupus treated with atacicept in a phase iib study (address ii). (21st March 2018) Authors: Merril, JT; Morand, E; Wallace, DJ; Kao, A; Vazquez-Mateo, C; Chang, P; Fleuranceau-Morel, P; Isenberg, DA Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 1 Page Start: A26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0272 Lack of association of glucocorticoid exposure and metabolic syndrome in sle. (15th June 2017) Authors: Apostolopoulos, D; Hoi, A; Morand, E Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 876 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗